Abstract
Introduction
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by proliferation of megakaryocytes and an increased risk of developing thrombohemorrhagic complications. 1 Current therapy for ET is not curative, and is therefore guided by the need to minimize the incidence of thrombohemorrhagic events, to control disease-related symptoms, and to reduce primary and iatrogenic disease progression, where possible. [2] [3] [4] The primary goal of cytoreductive therapy, recommended for patients with ET categorized as high-risk (> 60 years, or platelet count > 1500x10 9 /L, or a history of thrombohemorrhagic events 2 ), is to attain a complete clinicohematologic response (platelet count ≤ 400x10 9 /L, no disease-related symptoms, normal spleen size, white blood cell [WBC] count < 10x10 9 /L). [2] [3] [4] [5] [6] According to European LeukemiaNet (ELN) guidelines, hydroxycarbamide (HC) is currently recommended as first-line therapy in high-risk patients with ET, although its use should be carefully considered in younger patients (< 40 years old). 2 Anagrelide is indicated as second-line therapy in Europe for high-risk patients with ET who are intolerant to their current first-line therapy. 7 Other second-line therapies for management of ET include busulfan (licensed indication), interferon-α (IFN; unlicensed indication), and pipobroman (unlicensed indication). 5 Long-term treatment with cytoreductive agents can be accompanied by side effects often leading to dose reductions, which may in turn lead to reduced efficacy. As a means to overcome inadequate efficacy, or to avoid dose-limiting toxicities with monotherapy, combination therapy of two cytoreductive drugs, usually HC plus anagrelide, has been reported by the Anagrelide Study Group in around one-fifth of treated patients with ET. 8, 9 Moreover, a combination of anagrelide with either HC or IFN has been mentioned as a practical option for treatment of selected patients with ET [10] [11] [12] and recent clinical data are now available. [13] [14] [15] [16] There are currently no guidelines in place to guide the use of combination therapy in ET, thus the decision to undertake this treatment is at the discretion of the treating physician.
Evaluation of Xagrid ® Efficacy and Long-term Safety (EXELS) is a post-approval commitment observational study designed to monitor the safety and pregnancy outcomes of anagrelide and other cytoreductive therapies in a large European cohort of patients with ET.
In the EXELS study, a cohort of patients was identified as being treated with anagrelide in combination with another cytoreductive drug. The aim of this subanalysis is to describe the use of combination therapy in patients with ET, with a focus on HC + anagrelide, and to discuss its role in clinical practice.
Methods

Trial design
EXELS is an ongoing phase IV, observational, multicenter, safety study in high-risk patients with ET being treated with cytoreductive therapy (NCT00567502).
The primary objective of the EXELS study is to monitor safety and pregnancy outcomes of anagrelide and other cytoreductive therapies in high-risk patients with ET. Secondary objectives include assessment of efficacy (platelet reduction and incidence of thrombohemorrhagic events) and drug utilization (drug type, drug dose, and duration of exposure).
The study is being conducted in 13 European countries: Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, and the United Kingdom. All participating centers obtained ethical approval prior to enrolling patients and the study was conducted in accordance with the Declaration of Helsinki.
The first patient was registered in May 2005, and the last in April 2009; study completion is expected in June 2014. The analyses described here were performed on a planned data-cut in September 2011, 2.5 years after registration of the last patient.
Participants
Patients with a diagnosis of ET (according to Polycythemia Vera Study Group 17 or World Health Organization 1 criteria), with one or more high-risk features (> 60 years; history of thrombohemorrhagic events; initial platelet count of > 1000x10 9 /L) and receiving cytoreductive therapy, were eligible for inclusion in the study. Exclusion criteria were limited to the contraindications listed in the product information for each cytoreductive therapy used.
Written, informed consent was obtained from all patients prior to study participation.
Treatment
EXELS is a non-interventional study; the choice of cytoreductive therapy was determined prior to study registration and patients were managed according to local clinical practice at the discretion of the investigators.
Data related to thrombohemorrhagic events as collected per the predefined events in the protocol, suspected serious adverse events, platelet count, and any changes to medication were recorded at each 6-month update. Patients with multiple events of the same predefined event category were only counted once for each treatment received. All safety evaluations and procedures were performed in accordance with routine clinical practice.
Statistical methods
Data were collected using an electronic data capture system and were summarized using descriptive statistics. Combination treatments were included in the current analyses if they:
involved anagrelide in combination with another cytoreductive therapy; were taken for at least 30 days; and were the first combination received by the patient.
To eliminate data-input errors, a small number of data points were excluded using the following thresholds (considered to be outside of clinical practice): HC weekly doses reported as < 3500 mg or > 35,000 mg; anagrelide weekly doses of > 70 mg; platelet counts of < 10x10 9 /L or > 10,000x10 9 /L; WBC < 0.5x10 9 or > 150x10 9 ; hemoglobin (Hb) < 5 g/dL or > 22 g/dL; and hematocrit < 10% or > 70%..
Results
A total of 3643 high-risk patients with ET were enrolled in the EXELS study. Patient characteristics prior to starting combination therapy are shown in Table 1 . At the time of the planned data-cut in September 2011, 347 patients (9.5%) had received anagrelide in combination with another cytoreductive drug (HC, IFN, pipobroman, or other) at some stage during the observation period (Table 1) . HC + anagrelide was the most frequently prescribed combination therapy at registration or as first combination during the follow-up (n=304, 87.6%). The study investigators were not required to provide their reasons for starting patients on combination therapy. However, they did provide reasons for stopping monotherapy and therefore, by inference, the reasons for stopping the combination.
HC + anagrelide combination therapy -patients
In the 304 patients receiving HC + anagrelide, prior anagrelide monotherapy had been used Figure 1 ).
HC + anagrelide combination therapy -treatment
The median weekly doses of HC and anagrelide during prior monotherapy were 7000 mg and 10.5 mg, respectively. These initial median doses were not adjusted when a second agent was added. However, the median weekly dose of the added agent was lower during combination treatment than during monotherapy (HC 3500 mg and anagrelide 7 mg). 
HC + anagrelide combination therapy -blood cell counts
In patients receiving HC + anagrelide, the median platelet count recorded at diagnosis was 1001x10 9 /L (range: 432-2401). The last median platelet count recorded up to 6 months prior to starting combination therapy was 581x10 9 /L; this was reduced to a median platelet count of 411 and 434x10 9 /L at first and last evaluation, respectively, during combination therapy (Table 2 ). In patients who had received prior HC, median platelet count decreased from /L to 417x10 9 /L in patients who had received prior anagrelide. There was no significant difference between the prior treatment groups at any time point (Table 2) .
Paired data on platelet counts at 6 months prior to initiation of combination therapy and during the first 6 months of combination therapy were available in 153 cases. Significant increases in the proportion of patients with a platelet count Overall, similar trends in the proportions of patients reaching platelet counts
were observed when all available data were considered; 52.9%, 79.1%, and 77.0% for before combination, and during the first and final 6 months of combination therapy, respectively ( Figure 2 ). Three cases of thrombocytopenia were reported, of which two led to discontinuation; anagrelide was discontinued in one patient, and HC was discontinued in the other.
The median Hb level of patients receiving HC + anagrelide < 6 months prior to combination start was 11.9 g/dL (range: [8] [9] [10] [11] [12] [13] [14] [15] [16] . At the time of last testing during combination therapy, median hemoglobin levels were 14.1 g/dL (range: 9-15) in patients with no prior monotherapy (n=6), compared with 10.8 g/dL (range: 7-16) in patients with prior HC monotherapy (n=55) and 12.2 g/dL (8) (9) (10) (11) (12) (13) (14) (15) (16) in patients with prior anagrelide monotherapy (n=33). At the time of last testing during combination therapy, there was a greater proportion of patients with Hb levels < 10 g/dL among patients who had received prior monotherapy with HC (n=18/87; 20.7%) than with anagrelide (n=5/55; 9.1%). The median minimum Hb levels were similar between patients who achieved a platelet response versus those who did not achieve a platelet response both during the first 6 months and the last 6 months of combination therapy (all between 10.3 and 10.9 g/dL). 
Safety and tolerability
Predefined events were reported in 39 patients (12.8%) receiving HC + anagrelide as first combination, compared with 765 patients (21.0%) across the entire EXELS study population (n=3643; Table 3 ). The predefined events of cardiovascular symptoms (palpitations, tachycardia, hypotension, light headedness, dizziness, syncope, dyspnea on exertion, or peripheral edema) were the most frequently reported, and occurred in 15 patients (4.9%)
receiving HC + anagrelide as first combination and 152 patients (4.2%) in the total EXELS population. Transformations (including acute myeloid leukemia, myelofibrosis, and polycythemia vera) were the next most common, occurring in 7 patients (2.3%) receiving HC + anagrelide compared with 129 patients (3.5%) across the entire EXELS study population.
Death not attributed to a predefined event occurred in 4 patients (1.3%) in the HC + anagrelide group compared with 131 (3.6%) patients in the overall EXELS population. All other predefined events had an incidence of < 2.0% in both the HC + anagrelide group and the total EXELS population ( Table 3 ). The major thrombotic event rate in the HC + anagrelide group was 1.43% per patient year, and was higher in patients who stopped combination therapy compared with patients who continued combination therapy (2.89% vs.
0.82% per patient year). The major thrombotic rate was similar between patients who received prior anagrelide or HC therapy (0.41% and 0.31% per patient year, respectively).
A total of 158 (52.0%) patients discontinued HC + anagrelide combination therapy (Table 4) ; of these, HC was discontinued in 76 patients (48.1%), anagrelide was discontinued in 59 patients (37.3%), and both therapies were discontinued in 19 patients (12.0%). In a further 4 patients an additional therapy was added to their existing combination. Of the 95 patients who had received prior HC, 41 (43%) discontinued HC, 37 (39%) discontinued anagrelide, 13 (14%) discontinued both agents and 4 (4%) had an additional therapy added.
Of the 58 patients who had received prior anagrelide, 32 (55%) discontinued HC, 21 (36%) discontinued anagrelide and 5 (9%) discontinued both agents. The most common reasons reported by the investigators as causes for discontinuation were intolerance or side effects (n=75/158, 50.0%), lack of efficacy (n=35/158, 22.2%), and therapeutic strategy (including change of treatment) (n=34/158, 21.5%). In patients who had received prior HC, the frequency of discontinuation of either anagrelide or HC because of intolerance or side effects was similar (n=18/37, 49% and n=19/41, 46%, respectively). Intolerance or side effects was also the most frequent reason for discontinuing anagrelide or HC in patients who had received prior anagrelide (n=12/21, 57% and n=16/32, 50%, respectively).
At the time of the data-cut, a general trend was observed of increasing proportions of patients receiving HC + anagrelide over time, from registration (3.4%) to 5 years after registration (5.5%).
Discussion
The EXELS study provides valuable evidence of the cytoreductive therapies employed by physicians to treat high-risk patients with ET in a real-world setting across 13 European countries. Data reported elsewhere suggest that European physicians adhere to ELN guidelines and generally prescribe HC as first-line and anagrelide as second-line therapy. It is notable that irrespective of patients' initial monotherapy, discontinuations were most frequently attributed to intolerance. Of the patients who had received prior HC, neither HC nor anagrelide was discontinued more frequently. However, in those who had received prior anagrelide, 36% discontinued anagrelide while 55% discontinued HC; this suggests that some patients were being transitioned slowly from HC to anagrelide. Results from a recent study demonstrated that anagrelide was not inferior to HC in preventing thrombotic complications in patients with ET, 19 supporting the rationale for this transition. However, for some patients it is possible that the treatment strategy changed during the course of switching the patients from one therapy to another if the combination was found to be effective.
In the current study, it was noted that patients receiving HC + anagrelide were younger than the overall EXELS population of patients who received monotherapy (60.5 vs. 65.3 years, respectively; P=0.0002). It appears that some physicians may have considered platelet counts of < 600x10 9 /L indicative of insufficient efficacy of monotherapy (median prior to combination therapy was 581.0x10 9 /L) and elected to initiate combination therapy. Data suggest additional efficacy was achieved since median platelet counts reduced to 411.0x10 9 /L after initiation of combination therapy. It is not known why physicians elected to add a second therapy rather than further increasing the dose of the initial therapy. However, it is reasonable to hypothesize that they had concerns about the tolerability of increasing the dose of the initial therapy and chose to add an agent with different pharmacologic characteristics at a low dose.
Patients had received HC monotherapy for a significantly longer time period than anagrelide monotherapy (P<0.0001) before beginning combination therapy. It is possible that patients who started on anagrelide were switched to combination therapy more rapidly because they did not obtain a satisfactory response in a relatively short time and/or experienced more intolerable AEs.
Almost 80% of patients achieved platelet levels ≤ 600x10 9 /L within 6 months of starting HC + anagrelide, which was a marked increase from 53% prior to the combination. Thus, many patients with an unsatisfactory platelet response on monotherapy achieved an additional platelet-lowering effect with combination therapy. Furthermore, no significant difference in platelet levels was observed at any time point between patients who had received prior HC monotherapy and those who had received prior anagrelide monotherapy, suggesting that the platelet-lowering effects of HC + anagrelide are independent of prior monotherapy.
The ELN guidelines define a complete platelet response as ≤ 400x10 9 /L and a partial platelet response as ≤ 600x10 9 /L. 2 During the period of this study, physicians treating patients in EXELS were probably aiming to achieve complete platelet responses and the responses observed in our study were comparable to those observed in previous prospective studies. [19] [20] [21] These prospective studies indicated that a platelet response is important in reducing the thrombosis rate. However, recently an expert panel concluded that the ELN response criteria is insufficient as a measure of benefit for patients with ET. 22 This criticism was based on evidence from two retrospective studies that suggested complete clinicohematological responses and platelet count responses do not translate to reduced thrombosis risk. 23, 24 However, the low thrombosis rate observed in these retrospective studies was similar to that observed in the prospective studies, [19] [20] [21] which is perhaps not surprising considering the majority of patients in both retrospective studies achieved a complete or partial response.
Therefore, this criticism of the response criteria needs to be supported by prospective studies.
As expected, patients receiving long-term cytoreductive therapy tended to develop some degree of anemia. At the latest time point available, more patients who had received prior HC had Hb levels of 8-10 g/dL than those who had received prior anagrelide; treatmentnaïve patients were generally not anemic. These findings suggest that Hb levels are not fully recovered when anagrelide is added to prior HC monotherapy, possibly because the dose of HC is not reduced. Additionally, the lower dose of HC added to anagrelide monotherapy is not sufficient to cause marked anemia. Furthermore, when anagrelide and HC were started at the same time, where it is likely that both agents were given at slightly lower doses than in monotherapy, the patients also appeared to have a reduced risk of HC-induced anemia.
Although the most frequent reason for stopping HC + anagrelide was intolerance/side effects, the majority of patients who discontinued the combination stopped HC and continued with anagrelide monotherapy, similar to findings documented in the Registro Italiano Trombocitemia (RIT) report. 15 This may simply reflect physicians loosely following the recommended treatment algorithm (namely first-line HC, second-line anagrelide). In the current study, the number of patients who received anti-aggregatory therapy remained relatively constant before, during, and following discontinuation of HC + anagrelide therapy. This is perhaps a little surprising, as many of the patients continued with anagrelide monotherapy and the use of anti-aggregatory therapy with anagrelide is often discouraged.
25
The overall incidence of predefined events was, unexpectedly, lower in the population receiving the combination than in the overall EXELS population. This may be because patients who received the combination tended to be younger and therefore have a reduced probability of developing concurrent conditions. In this study, the rate of major thrombotic events in the HC + anagrelide group was 1.43% per patient year, which is comparable to the thrombotic event rate reported in previous HC monotherapy studies (1.66% 23 . 13, 14, 16 From the limited data available from these studies, the authors concluded that using HC and anagrelide in combination in lower doses than usually prescribed as monotherapy is being used by some physicians in selected patients with ET. Furthermore, in these studies it was found that the with combination therapy.
Summary
The EXELS study is the largest observational cohort of high-risk patients with ET reported to date. The study provides valuable data for the analysis of current cytoreductive therapies preferred by physicians. It has become evident in this analysis that combination therapy, particularly that of HC + anagrelide, is being employed by physicians in around 10% of patients. Also it was noted that patients received HC and anagrelide in combination, with or without concurrent anti-aggregatory therapy.
These real-world data have highlighted that a switch from monotherapy to HC + anagrelide combination therapy in a subgroup of high-risk patients with ET, while not recommended by current guidelines, is being utilized in clinical practice. Although platelet levels of
were achieved in almost 80% of patients receiving HC + anagrelide therapy, combination therapy was discontinued in approximately 50% of patients, most frequently for tolerability issues.
Further studies are warranted to define those patients in whom combination therapy may be an appropriate treatment option.
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